Video

Dr. Schiller on the Heterogeneity of AML

Gary J. Schiller, MD, discusses the heterogeneity of acute myeloid leukemia.

Gary J. Schiller, MD, director, Bone Marrow/Stem Cell Transplantation and professor of hematology/oncology, David Geffen School of Medicine, UCLA, discusses the heterogeneity of acute myeloid leukemia (AML).

Years ago, the panels for testing molecular abnormalities did not test many modern mutations, but chromosome 3 mutations could have been seen because conventional cytogenetics have been done for a long time, according to Schiller. Now patients live longer, relapse later, and there is more upfront management with allogeneic transplant—even in older populations, says Schiller.

Panels show more molecular mutations than ever before, but the disease biology has changed, as well. Relapse was “never seen” after 3 to 5 years in remission, according to Schiller, but that is no longer true. AML is changing, as is the ability to make a detailed diagnosis, concludes Schiller.

Related Videos
Dr Girard on De Novo and Acquired Resistance Alterations in HER2-Altered NSCLC
Elias Jabbour, MD
Daniel DeAngelo, MD, PhD
Douglas W. Sborov, MD, MS
Meletios (Thanos) Dimopoulos, MD, professor, therapeutics, Hematology Oncology, National and Kapodistrian University of Athens School of Medicine
Adam E. Singer, MD, PhD, Health Sciences Clinical Instructor, medicine, division lead, kidney cancer, Division of Hematology/Oncology, UCLA Health
Ami Umesh Badami, MD
Premal Thaker, MD, MS
Paul Chinfai Lee, MD, discusses the role of surgeons in regard to molecular testing in non–small cell lung cancer.
Neal D. Shore, MD, FACS